venBio Select Advisor LLC trimmed its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 0.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,360,000 shares of the biotechnology company’s stock after selling 8,103 shares during the period. BioMarin Pharmaceutical accounts for 6.9% of venBio Select Advisor LLC’s portfolio, making the stock its 5th biggest position. venBio Select Advisor LLC owned approximately 0.76% of BioMarin Pharmaceutical worth $115,804,000 as of its most recent SEC filing.
Several other large investors have also modified their holdings of BMRN. Doyle Wealth Management bought a new position in BioMarin Pharmaceutical in the 4th quarter valued at about $26,000. Commonwealth Bank of Australia grew its position in BioMarin Pharmaceutical by 49.6% in the 4th quarter. Commonwealth Bank of Australia now owns 350 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 116 shares in the last quarter. Lindbrook Capital LLC bought a new position in BioMarin Pharmaceutical in the 4th quarter valued at about $30,000. PRW Wealth Management LLC bought a new position in BioMarin Pharmaceutical in the 4th quarter valued at about $30,000. Finally, Exane Derivatives grew its position in BioMarin Pharmaceutical by 3,492.3% in the 4th quarter. Exane Derivatives now owns 467 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 454 shares in the last quarter. 99.81% of the stock is currently owned by institutional investors.
In other BioMarin Pharmaceutical news, CEO Jean Jacques Bienaime sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, December 26th. The shares were sold at an average price of $80.50, for a total value of $322,000.00. Following the completion of the transaction, the chief executive officer now directly owns 292,290 shares in the company, valued at $23,529,345. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director V Bryan Lawlis sold 2,150 shares of the firm’s stock in a transaction dated Thursday, December 27th. The stock was sold at an average price of $82.53, for a total transaction of $177,439.50. Following the completion of the transaction, the director now owns 21,310 shares of the company’s stock, valued at $1,758,714.30. The disclosure for this sale can be found here. Over the last quarter, insiders sold 55,346 shares of company stock valued at $4,998,770. Corporate insiders own 1.90% of the company’s stock.
Shares of NASDAQ:BMRN traded down $0.95 during trading hours on Friday, hitting $93.55. 6,875 shares of the company’s stock traded hands, compared to its average volume of 948,785. BioMarin Pharmaceutical Inc. has a 52 week low of $75.81 and a 52 week high of $106.74. The company has a current ratio of 3.93, a quick ratio of 2.92 and a debt-to-equity ratio of 0.28. The firm has a market cap of $17.01 billion, a price-to-earnings ratio of -283.88 and a beta of 1.53.
BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Thursday, February 21st. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.07. BioMarin Pharmaceutical had a negative net margin of 5.18% and a negative return on equity of 2.79%. The company had revenue of $353.00 million during the quarter, compared to analyst estimates of $377.35 million. During the same quarter last year, the firm posted $0.03 EPS. The business’s revenue for the quarter was down 1.4% on a year-over-year basis. On average, research analysts forecast that BioMarin Pharmaceutical Inc. will post 0.02 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This report was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://sportsperspectives.com/2019/03/15/venbio-select-advisor-llc-reduces-holdings-in-biomarin-pharmaceutical-inc-bmrn.html.
BioMarin Pharmaceutical Profile
BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.
Further Reading: Capital Gains
Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.